Logotype for Processa Pharmaceuticals Inc

Processa Pharmaceuticals (PCSA) Company presentation summary

Event summary combining transcript, slides, and related documents.

Logotype for Processa Pharmaceuticals Inc

Company presentation summary

14 Nov, 2026

Transaction and capital

  • Vidya’s equity was exchanged for common stock and newly created Series A non-voting convertible preferred stock in a sign-and-close reverse merger.

  • A concurrent $200M PIPE is designated for pipeline advancement, working capital and general corporate purposes; pro forma runway is expected into 2029, through multiple clinical milestones.

  • Expected capitalization after Series A conversion: 2.8M common shares plus 306.6M as-converted preferred shares, totaling 309.4M; subject to stockholder approval and beneficial ownership limits.

VT7208

  • Potentially best-in-class, once-daily oral BTK inhibitor with preclinical potency, peripheral and CNS target engagement, and consistent efficacy across disease models.

  • Phase 1 showed favorable safety and tolerability across evaluated doses, with no dose-limiting toxicities, serious adverse events, treatment-related discontinuations, liver safety signal or bleeding-related events.

  • Median half-life was ~6 hours, supporting once-daily dosing; exposure increased near dose-proportionally and BTK occupancy remained ≥95% for 48 hours after the last dose.

  • Phase 2 initiation and proof-of-concept data targeted: food allergy H2 2026 and H2 2027; CSU H2 2026 and H1 2028; relapsing MS H1 2027 and H2 2028.

Oral FcRn program

  • Research collaboration and exclusive option with Generian Pharmaceuticals covers a macrocyclic peptide against the clinically validated FcRn target; work is in lead optimization through development-candidate nomination.

  • FcRn blockade directs pathogenic IgG, including autoantibodies, to degradation; the mechanism may address IgG-driven diseases including MG, CIDP, ITP and wAIHA.

  • VYVGART generated $4.15B in 2025 global net sales, up 90% vs. 2024; development-candidate nomination for the oral program is targeted for 2H 2027.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Processa Pharmaceuticals